On August 12, Ki-ryong Kim, a researcher at Yuanta Securities, stated, "The characteristics of Samsung C&T's performance are 1) steady profit realization in the construction sector, 2) sharp profit growth of Samsung Biologics, which successfully turned profitable in Q3 2019, and 3) losses in the fashion and leisure sectors in the first half of 2020 due to COVID-19. Going forward, the company's earnings are expected to continue growing centered on construction and bio sectors, with operating profit in 2021 estimated to increase by 28% year-on-year to 1.16 trillion KRW, driven by a turnaround to profitability in the fashion and leisure sectors, which had been operating at a loss due to COVID-19." He set the target price for Samsung C&T at 180,000 KRW.
Over the past five days, individual investors have net sold 524,282 shares of Samsung C&T, while foreigners and institutions have net sold 81,341 shares and net bought 649,292 shares, respectively.

※ This article was generated in real-time by an automated article generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
![Clutching a Stolen Dior Bag, Saying "I Hate Being Poor but Real"... The Grotesque Con of a "Human Knockoff" [Slate]](https://cwcontent.asiae.co.kr/asiaresize/183/2026021902243444107_1771435474.jpg)
